Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ovid Therapeutics Inc.OVID · Entity 5411 | CBFO | February 23, 2026 | March 02, 2026 |
| S&W Seed CoSANW · Entity 81242 | Director | December 17, 2024 | December 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ovid Therapeutics Inc.
Report date February 23, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,188 |
Reported balance
After 2026-02-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-02-23 · Sale · Disposed 8,541 · Balance 88,188 F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes 28,756 shares acquired under the Issuer's employee stock purchase plan. |
| Common StockSEC Table I · non-derivative | Direct | 156,313 |
Reported balance
After 2026-02-26 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-02-26 · Grant · Acquired 68,125 · Balance 156,313 F4: Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date. F5: Each RSU represents a contingent right to receive one share of Common Stock. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-02-25 | Direct | 408,750 |
Reported balance
After 2026-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-26 · Grant · Acquired 408,750 · Balance 408,750 F6: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes 28,756 shares acquired under the Issuer's employee stock purchase plan.
F4: Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date.
F5: Each RSU represents a contingent right to receive one share of Common Stock.
F6: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.
S&W Seed Co
Report date December 17, 2024 · Filed December 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,700 |
Reported balance
After 2024-12-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-12-17 · Grant · Acquired 12,725 · Balance 20,700 F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) December 17, 2025 and (ii) the date of the Issuer's next Annual Meeting of Stockholders, in each case, subject to the Reporting Person's continuous service on such date. F2: This total reflects the 1-for-19 reverse split of Issuer's common stock that occurred on October 17, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) December 17, 2025 and (ii) the date of the Issuer's next Annual Meeting of Stockholders, in each case, subject to the Reporting Person's continuous service on such date.
F2: This total reflects the 1-for-19 reverse split of Issuer's common stock that occurred on October 17, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed Mar 2, 2026 21:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 408,750 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001311404-26-000002 · form4-03022026_040305.xml · derivative · entry 3 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,750 Underlying: Common Stock · 408,750 shares Expires 2036-02-25 F6 · derivative.exercise_date: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock | 68,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001311404-26-000002 · form4-03022026_040305.xml · nonDerivative · entry 2 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,313 F4 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 20, 2027, subject to the Reporting Person's continuous service through each such vesting date. F5 · price: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| February 23, 2026 Filed Mar 2, 2026 21:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | SaleCommon Stock | 8,541 | $1.45 | $12,384.45 |
DisclosureSEC source: 0001311404-26-000002 · form4-03022026_040305.xml · nonDerivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,188 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.45 to $1.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 28,756 shares acquired under the Issuer's employee stock purchase plan. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:15 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | SaleCommon Stock | 3,902 | $0.56 | $2,185.12 |
DisclosureSEC source: 0001415889-25-005997 · form4-02282025_040201.xml · nonDerivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,973 F1 · shares: Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person. Read SEC document |
| February 20, 2025 Filed Feb 25, 2025 00:55 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 262,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-25-005367 · form4-02242025_070203.xml · derivative · entry 2 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2035-02-19 F3 · derivative.exercise_date: The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date. Read SEC document |
| February 20, 2025 Filed Feb 25, 2025 00:55 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005367 · form4-02242025_070203.xml · nonDerivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,875 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 16:30 UTC | S&W Seed Co SANW · Entity 81242 | GrantCommon Stock | 12,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-029863 · form4-12192024_041219.xml · nonDerivative · entry 1 Rona Jeffrey A · CIK 0001311404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,700 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) December 17, 2025 and (ii) the date of the Issuer's next Annual Meeting of Stockholders, in each case, subject to the Reporting Person's continuous service on such date. F2 · balance_after: This total reflects the 1-for-19 reverse split of Issuer's common stock that occurred on October 17, 2024. Read SEC document |
| July 30, 2024 Filed Aug 1, 2024 21:00 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (right to buy) · Derivative | 315,000 | $0.00 Strike: $1.05 | $0.00 |
DisclosureSEC source: 0001415889-24-020526 · form4-08012024_050801.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,000 Underlying: Common Stock · 315,000 shares Expires 2034-07-29 F1 · derivative.exercise_date: 50% of the shares subject to the option shall vest on July 30, 2025, and the remaining shares subject to the option shall vest in 12 equal monthly installments thereafter, subject to Reporting Person's continuous service on each such date. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 23:03 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 168,750 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001209191-24-003970 · doc4.xml · derivative · entry 2 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 168,750 shares Expires 2034-02-21 F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 22, 2025 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continued services through such date. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 23:03 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantCommon Stock | 28,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003970 · doc4.xml · nonDerivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,125 F1 · shares: Represents a restricted stock unit (RSU) award. One-third (1/3) of the total number of RSUs shall vest on January 1, 2025 and one-third (1/3) of the remaining RSUs shall vest each year thereafter on anniversary of the vesting commencement date, subject to the Reporting Person's continuous service through such vesting date. F2 · price: Each RSU represents a contingent right to receive one share of Common Stock. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 17:18 UTC | S&W Seed Co SANW · Entity 81242 | GrantCommon Stock | 151,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059219 · doc4.xml · nonDerivative · entry 1 Rona Jeffrey A · CIK 0001311404 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,525 F1 · shares: Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in full on the earlier of (i) December 13, 2024 and (ii) the date of the Issuer's next Annual Meeting of Stockholders, in each case, subject to the Reporting Person's continuous service on such date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:24 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-013301 · doc4.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-02-22 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2024 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:34 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-024187 · doc4.xml · derivative · entry 2 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-07 F2 · derivative.exercise_date: The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 21:34 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 194,399 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-024187 · doc4.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,399 Underlying: Common Stock · 194,399 shares Expires 2032-04-07 F1 · derivative.exercise_date: The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 03, 2022 Filed Feb 4, 2022 23:22 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 218,750 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-22-007311 · doc4.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · CBFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,750 Underlying: Common Stock · 218,750 shares Expires 2032-02-02 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 3, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| June 02, 2021 Filed Jun 10, 2021 23:49 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.42 | $0.00 |
DisclosureSEC source: 0001209191-21-039670 · doc4.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-01 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on June 2, 2022 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| December 17, 2020 Filed Dec 21, 2020 21:58 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001209191-20-064666 · doc4.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on December 17, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
| October 11, 2020 Filed Oct 13, 2020 20:46 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-20-054653 · doc4.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-10-10 F1 · derivative.exercise_date: 50% of the shares subject to the Stock Option will vest and become exercisable on October 11, 2021 and the remaining shares will vest in 12 equal installments thereafter, subject to the Reporting Person's continued service through each such date. Read SEC document |
| September 30, 2020 Filed Oct 3, 2020 01:40 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $5.74 | $0.00 |
DisclosureSEC source: 0001209191-20-053411 · doc4.xml · derivative · entry 1 Rona Jeffrey A · CIK 0001311404 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2030-09-29 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on September 30, 2021 and the remaining shares will vest in 36 equal monthly installments thereafter subject to the Reporting Person's continued services through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.